 Patients undergo blood sample collection and bone marrow biopsyaspiration periodically for translational research studies. Samples are analyzed by flow cytometry for assessment of minimal residual disease. Molecular prognostic markers including CD38, ZAP-70, IgVH gene mutation status, and cytogenetic abnormalities by FISH, Tcl-1 and CD49d protein expression, and immunoglobulin heavy chain D and J family gene usage are also analyzed. Plasma samples are stored for future studies evaluating levels of VEGF, bFGF, and thrombospondin by ELISA. 